The coronary angiogenetic effect of heparin: Experimental basis and clinical evidence

Angiology

Volumn 48, Issue 11, 1997, Pages 969-976

  Bombardini, Tonino ^a   Picano, Eugenio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ANTICOAGULANT AGENT; HEPARIN; MITOGENIC AGENT;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA ANALYSIS; DISEASE ASSOCIATION; EXERCISE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; THROMBOSIS;

EID: 0030699291     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979704801106     Document Type: Article

References (44)

1. Schaper W, Sharma HS, Quinkler W, et al: Molecular biologic concepts of coronary anastomoses. J Am Coll Cardiol 15:513-518, 1990.
2. Kass RW, Kotler MN, Yazdanfar S: Stimulation of coronary collateral growth: Current developments in angiogenesis and future clinical applications. Am Heart J 123:486-496, 1992.
3. Maseri A: Experimental models of acute myocardial ischemia. In Ischemic Heart Disease, ed. by Maseri A. London: Churchill Livingstone, 1995, pp 139-162.
4. Schaper W: The Collateral Circulation of the Heart. New York: Elsevier, 1971.
5. Khouri EM, Gregg DE, McGranaham GM: Regression and reappearance of coronary collaterals. Am J Physiol 220:655, 1971.
6. Lambert PR, Hess DS, Bache RJ: Effect of exercise on perfusion of collateral-dependent myocardium in dogs with chronic coronary artery occlusion. J Clin Invest 59:1-11, 1977.
7. Feldman RL, Pepine CJ: Evaluation of coronary collateral circulation in conscious humans. Am J Cardiol 53:1233-1238, 1984.
8. Cohen M, Rentrop KP: Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: A prospective study. Circulation 74:469-476, 1986.
9. Sabia PJ, Powers ER, Ragosta M, et al: An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 327:1825-1831, 1992.
10. Habib GB, Heibig J, Forman SA, et al and the TIMI Investigators: Influence of coronary collateral vessels on myocardial infarct size in humans: Results of phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Circulation 83:739-746, 1991.
11. Hiray T, Fujita M, Nakajima H, et al: Importance of collateral circulation for prevention of left ventricular aneurysm formation in acute myocardial infarction. Circulation 79:791-796, 1989.
12. Gliozheni E, Picano E, Bernardino L, et al: Angiographically assessed coronary collateral circulation increases vulnerability to myocardial ischemia during vasodilator stress testing. Am J Cardiol 78:12, 1996.
13. Sasayama S, Fujita M: Recent insights into coronary collateral circulation. Circulation 85:1197-1204, 1992.
14. Sasayama S: Effect of coronary collateral circulation on myocardial ischemia and ventricular dysfunction. Cardiovasc Drugs Ther 8:327-334, 1994.
15. Mall G, Schikora I, Mattfeldt T, et al: Dipyridamole-induced neoformation of capillaries in the rat heart: Quantitative sterological study on papillary muscles. Lab Invest 57:86-93, 1987.
16. Symons JD, Firoozmand E, Longhurst JC: Repeated dipyridamole administration enhances collateral-dependent flow and regional function during exercise: A role for adenosine. Circ Res 73:503-513, 1993.
17. Yanagisawa-Miwa A, Uchida Y, et al: Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257:1401-1403, 1992.
18. Unger EF, Banai S, Shou M, et al: Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 266:H1588-H1595, 1994.
19. Banai S, Jaklitsch MT, Shou M, et al: Angiogenic induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183-2189, 1994.
20. Ferrara N, Houck KA, Jakman LB, et al: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endo Rev 13:18-32, 1992.
21. Azizkhan RG, Azizkhan JC, Zetter BR, et al: Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med 152:931-944, 1980.
22. Taylor S, Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297:307-312, 1982.
23. Folkman J, Shing Y: Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 313:355-364, 1992.
24. Schott RJ Morrow LA: Growth factors and angiogenesis. Cardiovasc Res 27:1155-1161, 1993.
25. Folkman J, Klagsbrun M, Sasse J, et al: A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 130:393-400, 1988.
26. Ruoslahti E, Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell 64:867-869, 1991.
27. Ferrara N, Houck KA, Jakman LB, et al: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endo Rev 13:18-32, 1992.
28. Brogi E, Wu T, Namiki A, et al: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 90:649-652, 1994.
29. D'Amore PA, Thompson RW: Collateralization in peripheral vascular disease. In: Vascular Disease, ed. by Strandness DE, Didisheim P, Clowes AW, et al. New York: Grune and Stratton, 1987, pp 319-333.
30. Stavri GT, Zachary IC, Baskerville PA, et al: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation 92:11-14, 1995.
31. Fujita M, Mikuniya A, Takahashi M, et al: Acceleration of coronary collateral development by heparin in conscious dogs. Jpn Circ J 51:395-402, 1987.
32. Carrol SM, White FC, Roth DM, et al: Heparin accelerates coronary collateral development in a porcine model of coronary artery occlusion. Circulation 88: 198-207, 1993.
33. Unger EF, Sheffield CD, Epstein SE: Heparin promotes the formation of extracardiac to coronary anastomoses in a canine model. Am J Physiol 260:H1625-H1634, 1991.
34. Yang HT, Ogilvie RW, Terjung RL: Heparin increases exercise-induced collateral blood flow in rats with femoral artery ligation. Circ Res 76:448-456, 1995.
35. Fujita M, Sasayama S, Asanoi H, et al: Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 77:1022-1029, 1988.
36. Fujita M, Yamanishi K, Hirai T, et al: Comparative effect of heparin treatment with and without strenuous exercise on treadmill capacity in patients with stable effort angina. Am Heart J 122:453-457, 1991.
37. Quyyumi AA, Diodati JG, Lakatos E, et al: Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study. J Am Coll Cardiol 22:635-641, 1993.
38. Robinson LA: Angiogenesis and low molecular weight heparin. J Am Coll Cardiol 24:271-274 (letter), 1994.
39. Gagliardi JA, Preds NG, Menins JC, et al: Exercise training and heparin pretreatment in patients with coronary artery disease. Am Heart J 132:946-951, 1996.
40. Soker S, Goldstaub D, Svahn CM, et al: Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF 165 to its receptors. Bioch and Biophys Res Commun 203:1339-1347, 1994.
41. Ornitz DM, Yayon A, Flanagan JG, et al: Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cell. Mol Cell Biol 12:240-247, 1992.
42. Fitzgerald GA: Dipyridamole. N Engl J Med 316: 1247-1257, 1987.
43. Pearlman JD, Hibbered MG, Chuang ML, et al: Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med 1:1085-1089, 1995.
44. Giordano FJ, Ping P, McKirnan MD, et al: Intra-coronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2:534-539, 1996.